Micro X (ASX:MX1) - CEO, Peter Rowland
CEO, Peter Rowland
Source: SBS
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australian hi-tech company Micro-X (MX1) has received $1.2 million in purchase orders for its digital X-ray system, Nano
  • The majority of these orders come from Australian customers
  • One such client is the New South Wales Government, who purchased x-ray systems as it prepares to combat COVID-19
  • This order represents the first major sale of Nano units on the Australian market, following Micro-X’s first placement at Alfred Hospital
  • It brings the total orders for Nano to $3.6 million since February 2020
  • On market close, Micro-X is up 12 per cent and is trading for 14¢ per share

Australian hi-tech company Micro-X (MX1) has received $1.2 million in purchase orders for its digital X-ray system, Nano.

The majority of these orders come from Australian customers. One such client is the New South Wales Government, who purchased x-ray systems as it prepares to combat COVID-19. The other $200,000 in purchase orders has been received from European and Asian markets.

This order represents the first major sale of Nano units on the Australian market, following Micro-X’s first placement at Alfred Hospital.

According to the company, Nano is a lightweight, digital medical x-ray system.

The recent purchase orders were generated by Quantum Health Group, a healthcare distribution company which specialises in medical imaging equipment throughout Asia.

As announced last week, the company has begun a major ramp-up in Nano production to meet growing demand for mobile x-ray imaging.

Managing Director Peter Rowland said there has been an explosion for the demand around the globe for imaging technology in the response to COVID-19.

“As Australian government agencies increase their state of readiness to image potentially many more Australian patients, we are very pleased that our locally developed and manufactured high-tech Nano is now helping Australians in these very challenging times,” he said.

“Our recent investment to ramp up Nano production and reduce delivery times will enable these additional orders to be filled promptly and for us to continue to meet expected ongoing demand for new orders as and when they are received,” he added.

This new order brings the total orders for Nano to $3.6 million since February 2020.

On market close, Micro-X is up 12 per cent and is trading for 14¢ per share.

MX1 by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…